View Older Stories View More Recent Stories
-
AquaVenture Holdings Files Registration Statement for Proposed Initial Public Offering
-
Axovant Sciences (AXON) Defended at RBC Capital
-
Stronger U.S. second quarter growth backs case for Fed hike
-
RBC Capital Raises Price Target on Marvell Technology (MRVL) Following Announced Downsize of Mobile Platform
-
RBC Capital Cuts Price Target on TE Connectivity (TEL) to Reflect Chinese and Industrial Headwinds
-
RBC Capital Cutus Price target on Sensata Technologies (ST) to Reflect Headwinds
-
RBC Capital Cuts Price Target on Hexcel Corp. (HXL) Following Investor Meetings
-
RBC Capital Upgrades Autoliv, Inc. (ALV) to Sector Perform
-
Concordia Healthcare Announces Terms of US$520 Million Public Offering of Common Shares
-
TZMI Congress 2015 – Programme Now Online
-
Canadian Utilities Limited Announces Closing of $250 Million Preferred Share Issue
-
RBC Capital Starts CareTrust REIT (CTRE) at Outperform
-
Dollar, shares gain on Yellen speech, U.S. GDP
-
Aircastle to Present at RBC Capital Markets Aircraft Leasing Investor Day Conference
-
Nabriva Therapeutics Announces Closing of Its Initial Public Offering
-
Vertex (VRTX) Concerns Overdone, Buy Weakness - RBC Capital
-
RBC Capital Defends Vertex Pharma (VRTX) Following Competition Speculation; Affirms at 'Outperform'
-
RBC Capital Reiterates Sector Perform on ConAgra Foods (CAG) Following 1Q16 EPS Beat
-
RBC Capital Reiterates Sector Perform on Darden Restaurants (DRI) Following Sum of Parts Analysis
-
RBC Capital Remains Bullish on General Mills (GIS) Following EPS Beat
-
Intra-Cellular Therapies (ITCI) Prices 6.9M Common Stock Offering at $43.50/Share
-
China Sept flash factory PMI unexpectedly falls to six-and-a-half year low
-
Sun Life Financial announces offering of Subordinated Unsecured Debentures
-
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
-
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
-
Fitch Rates NYC Transitional Finance Auth's Fiscal 2016 Subseries A-4 'AAA/F1 & A-5 'AAA/F1+'
-
Fitch to Rate Metro Washington Airports Auth Var Rate Refunding Bonds Series 2011A 'AAA/F1+'
-
Streetinsider.com's Hot Lunchtime Reads 9/22: (MGM) (LEN) (WFM) (ST)
-
VW Impact on Sensata Technologies (ST) Seen as 'Immaterial', RBC Capital Says
-
RBC Capital Starts Frontier Communications (FTR) at Sector Perform
-
RBC Capital Starts Cogent Communications (CCOI) at Outperform
-
RBC Capital Starts QTS Realty Trust (QTS) at Outperform
-
RBC Capital Starts CenturyLink, Inc. (CTL) at Sector Perform
-
RBC Capital Starts Level 3 Communications (LVLT) at Outperform
-
RBC Capital Starts Main Street Capital (MAIN) at Outperform
-
RBC Capital Downgrades DuPont Fabros Technology (DFT) to Sector Perform
-
Intra-Cellular Therapies (ITCI) to Offer $300M in Common Stock
-
Intra-Cellular Therapies (ITCI) Commences $300M Common Stock Offering
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
Streetinsider.com's Hot Lunchtime Reads 9/21: (MNK) (BBRY) (AMZN) (P)
-
AcelRx Pharma (ACRX) Strengthens Cash Position for Regulatory with Zalviso Monetization - RBC Capital
-
Dates Announced for the 18th Annual ICR Conference
-
RBC Capital Downgrades Anheuser-Busch InBev (BUD) to Sector Perform
-
Concordia Healthcare (CXRX) Files to Sell up to 8M Common Shares
-
Concordia Healthcare Announces Public Offering of Common Shares
-
RBC Capital Starts Callon Petroleum (CPE) at Sector Perform
-
RBC Capital Downgrades Precision Castparts (PCP) to Sector Perform Amid Pending Takeover
-
Toromont Prices Private Offering of Cdn$150 Million 3.71% Senior Unsecured Notes Due 2025
-
ImmunoGen (IMGN) Reveals Mirvetuximab Phase II Design at Investor Day; RBC Affirms at 'Outperform'
-
Nabriva Therapeutics AG (NBRV) IPO Opens Up 8%


